| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/01.CJI.0000192105.24583.83 |
| P698 | PubMed publication ID | 16365595 |
| P2093 | author name string | Louis M Weiner | |
| P433 | issue | 1 | |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1-9 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | Fully human therapeutic monoclonal antibodies | |
| P478 | volume | 29 |
| Q35007370 | A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use. |
| Q24613552 | Affinity and avidity in antibody-based tumor targeting |
| Q58007992 | Antibody Phage Display |
| Q31814859 | Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody |
| Q50926799 | Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. |
| Q35232352 | Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. |
| Q35901092 | Clinical development of anti-RANKL therapy |
| Q37810423 | Denosumab for the Management of Postmenopausal Osteoporosis |
| Q51722272 | Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. |
| Q37561771 | EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new? |
| Q84859300 | Expanding horizons in metastatic prostate cancer treatment |
| Q34527769 | Frontier of therapeutic antibody discovery: The challenges and how to face them |
| Q81376179 | Future challenges |
| Q64951358 | Immunogenicity of biologic agents: a new concern for the practicing rheumatologist? |
| Q34070944 | Immunogenicity of panitumumab in combination chemotherapy clinical trials |
| Q37393024 | Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies |
| Q24653374 | Immunotoxicity of monoclonal antibodies |
| Q38310029 | Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization |
| Q39257411 | In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours |
| Q38161993 | In vivo applications of magnetic nanoparticle hyperthermia |
| Q34389834 | Inhibition of osteoclastogenesis by RNA interference targeting RANK. |
| Q44086832 | Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. |
| Q37563941 | Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display |
| Q33588489 | Mining human antibody repertoires |
| Q38155649 | Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor |
| Q36653343 | Mucosal injury from targeted anti-cancer therapy. |
| Q36597647 | Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs |
| Q34621577 | New trends in epidermal growth factor receptor-directed monoclonal antibodies |
| Q26747776 | PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab |
| Q28238311 | Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study |
| Q37756126 | Panitumumab: a review of its use in metastatic colorectal cancer |
| Q36651665 | Panitumumab: in the treatment of metastatic colorectal cancer |
| Q37827324 | Phage display for the generation of antibodies for proteome research, diagnostics and therapy. |
| Q37274670 | Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers |
| Q38072598 | Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies |
| Q35758412 | Qualification and application of a liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of trastuzumab in rat plasma. |
| Q38628086 | Quantitative MS analysis of therapeutic mAbs and their glycosylation for pharmacokinetics study |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q37027607 | Research and development of therapeutic mAbs: An analysis based on pipeline projects |
| Q38009712 | Skeletal and extraskeletal actions of denosumab. |
| Q92144029 | The pharmacology and therapeutic applications of monoclonal antibodies |
| Q38572163 | The present state of the art in expression, production and characterization of monoclonal antibodies |
| Q37826197 | The role and efficacy of denosumab in the treatment of osteoporosis: an update |
| Q24633284 | The role of RANK-ligand inhibition in cancer: the story of denosumab |
| Q38056541 | The role of osteoprotegerin in cardiovascular disease |
| Q37409192 | Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma |
| Q41662108 | Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody |
Search more.